Oesophageal Cancer Trial, Recruiting NCT03183115 Sponsor: E-DA Hospital Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT03183115
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who have been diagnosed with an early-stage oesophageal condition (such as high-grade abnormal cells, cancer in place, or a very early-stage cancer that has not spread) and who were treated with a procedure called endoscopic submucosal dissection (a technique to remove abnormal tissue from the food pipe lining).
  • People whose food pipe lining showed a specific pattern during a dye test (called Lugol staining), where more than 10 small patchy areas did not take up the dye, creating a "speckled" appearance.

Who may not be able to join:

  • People who had an incomplete endoscopic (camera-based) treatment, or who experienced serious complications during or after their procedure, such as a perforation (a hole in the food pipe) or a stricture (narrowing of the food pipe).
  • People who have previously had chemotherapy (cancer-fighting medication given through the whole body) or radiation therapy aimed at the oesophagus (food pipe), or who have had their oesophagus surgically removed.
  • People whose life expectancy is estimated to be less than 2 years.
  • People with severe, advanced liver disease that is no longer responding well to treatment (confirm with trial site).
  • People who have large swollen veins in the oesophagus (a condition related to liver disease).
  • People in poor general health who are unable to carry out basic daily activities (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 886-7-6150011

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
E-DA Hospital
Registry
ClinicalTrials.gov
Start date
18 April 2016
Est. completion
30 October 2025

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Tumor recurrence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov